A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C)

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 50-59

  Saiko, Philipp ^a   Graser, Geraldine ^a   Giessrigl, Benedikt ^a   Lackner, Andreas ^a   Grusch, Michael ^a   Krupitza, Georg ^a   Basu, Arijit ^b   Sinha, Barij Nayan ^b   Jayaprakash, Venkatesan ^b   Jaeger, Walter ^c   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arabinofuranosylcytosine; Cell cycle arrest; N hydroxy N' aminoguanidines; Ribonucleotide reductase; Synergistic combination effects

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYTARABINE; CYTIDINE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; GUANIDINE DERIVATIVE; N HYDROXY 2 (ANTHRACENE 2 YL METHYLENE) HYDRAZINECARBOXIMIDAMIDE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CANCER CHEMOTHERAPY; CELL STRAIN HL 60; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPHOSPHORYLATION; UPREGULATION;

CELL CYCLE PROTEINS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANIDINES; HL-60 CELLS; HUMANS; IMMUNOGLOBULIN G; MELPHALAN; MOLECULAR STRUCTURE; RIBONUCLEOTIDE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78549281372     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.006     Document Type: Article

References (57)

1. Koneru P.B., Lien E.J. Avramis VI. Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C). Pharmaceutical Research 1993, 10:515-520.
2. Ren S., Wang R., Komatsu K., Bonaz-Krause P., Zyrianov Y., McKenna C.E., et al. Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. Journal of Medicinal Chemistry 2002, 45:410-419.
3. Tai A.W, Lien E.J., Lai M.M., Khwaja T.A. Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents. Journal of Medicinal Chemistry 1984, 27:236-238.
4. T'Ang A., Lien E.J., Lai M.M. Optimization of the Schiff bases of N-hydroxy-N'-aminoguanidine as anticancer and antiviral agents. Journal of Medicinal Chemistry 1985, 28:1103-1106.
5. van't Riet B., Wampler G.L., Elford H.L. Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. Journal of Medicinal Chemistry 1979, 22:589-592.
6. Matsumoto M., Fox J.G., Wang P.H., Koneru P.B., Lien E.J., Cory J.G. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives. Biochemical Pharmacology 1990, 40:1779-1783.
7. Takeda E., Weber G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sciences 1981, 28:1007-1014.
8. Kolberg M., Strand K.R., Graff P., Andersson K.K. Structure, function, and mechanism of ribonucleotide reductases. Biochimica et Biophysica Acta 2004, 1699:1-34.
9. Shao J., Zhou B., Chu B., Yen Y. Ribonucleotide reductase inhibitors and future drug design. Current Cancer Drug Targets 2006, 6:409-431.
10. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nature Genetics 2007, 39:776-780.
11. Saban N., Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemotherapy and Pharmacology 2009, 64:213-221.
12. Tennant L. Chronic myelogenous leukemia: an overview. Clinical Journal of Oncology Nursing 2001, 5:218-219.
13. Noble S., Goa K.L., Gemcitabine A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54:447-472.
14. Toschi L., Finocchiaro G., Bartolini S., Gioia V., Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncology 2005, 1:7-17.
15. Hatse S., De Clercq E., Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochemical Pharmacology 1999, 58:539-555.
16. Abeysinghe R.D., Greene B.T., Haynes R., Willingham M.C., Turner J., Planalp R.P., et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001, 22:1607-1614.
17. Samuni A.M., Krishna M.C., DeGraff W., Russo A., Planalp R.P., Brechbiel M.W., et al. Mechanisms underlying the cytotoxic effects of Tachpyr-a novel metal chelator. Biochimica et Biophysica Acta 2002, 1571:211-218.
18. Turner J., Koumenis C., Kute T.E., Planalp R.P., Brechbiel M.W., Beardsley D., et al. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood 2005, 106:3191-3199.
19. Torti S.V., Torti F.M., Whitman S.P., Brechbiel M.W., Park G., Planalp R.P. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998, 92:1384-1389.
20. Greene B.T., Thorburn J., Willingham M.C., Thorburn A., Planalp R.P., Brechbiel M.W., et al. Activation of caspase pathways during iron chelator-mediated apoptosis. Journal Biological Chemistry 2002, 277:25568-25575.
21. Tsimberidou A.M., Alvarado Y., Giles F.J. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Review of Anticancer Theraphy 2002, 2:437-448.
22. Erlichman C., Fine S., Wong A., Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 1988, 6:469-475.
23. Saiko P., Ozsvar-Kozma M., Bernhaus A., Jaschke M., Graser G., Lackner A., et al. N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. International Journal of Oncology 2007, 31:1261-1266.
24. Horvath Z., Saiko P., Illmer C., Madlener S., Hoechtl T., Bauer W., et al. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Experimental Hematology 2005, 33:329-335.
25. Horvath Z., Murias M., Saiko P., Erker T., Handler N., Madlener S., et al. Cytotoxic and biochemical effects of 3,3',4,4',5,5'-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells. Experimental Hematology 2006, 34:1377-1384.
26. Fritzer-Szekeres M., Salamon A., Grusch M., Horvath Z., Hochtl T., Steinbrugger R., et al. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. Biochemical Pharmacology 2002, 64:481-485.
27. Fritzer-Szekeres M., Savinc I., Horvath Z., Saiko P., Pemberger M., Graser G., et al. Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells-synergism with Ara-C. International Journal of Oncology 2008, 33:887-892.
28. Szekeres T., Gharehbaghi K., Fritzer M., Woody M., Srivastava A., van't Riet B., et al. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology 1994, 34:63-66.
29. Garrett C., Santi D.V. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Analytical Biochemistry 1979, 99:268-273.
30. Grusch M., Polgar D., Gfatter S., Leuhuber K., Huettenbrenner S., Leisser C., et al. Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death and Differentiation 2002, 9:169-178.
31. Grasl-Kraupp B., Ruttkay-Nedecky B., Koudelka H., Bukowska K., Bursch W., Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995, 21:1465-1468.
32. Rosenberger G., Fuhrmann G., Grusch M., Fassl S., Elford H.L., Smid K., et al. The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sciences 2000, 67:3131-3142.
33. Grusch M., Fritzer-Szekeres M., Fuhrmann G., Rosenberger G., Luxbacher C., Elford H.L., et al. Activation of caspases and induction of apoptosis by novel ribonucleotide reductase inhibitors amidox and didox. Experimental Hematology 2001, 29:623-632.
34. Fritzer-Szekeres M., Grusch M., Luxbacher C., Horvath S., Krupitza G., Elford H.L., et al. Trimidox, an inhibitor of ribonucleotide reductase, induces apoptosis and activates caspases in HL-60 promyelocytic leukemia cells. Experimental Hematology 2000, 28:924-930.
35. Huettenbrenner S., Maier S., Leisser C., Polgar D., Strasser S., Grusch M., et al. The evolution of cell death programs as prerequisites of multicellularity. Mutation Research 2003, 543:235-249.
36. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984, 22:27-55.
37. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. European Journal of Biochemistry (FEBS) 1981, 115:207-216.
38. Szekeres T., Fritzer M., Strobl H., Gharehbaghi K., Findenig G., Elford H.L., et al. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells. Blood 1994, 84:4316-4321.
39. Chimploy K., Diaz G.D., Li Q., Carter O., Dashwood W.M., Mathews C.K., et al. E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin. International Journal of Cancer 2009, 125:2086-2094.
40. Yarbro J.W. Mechanism of action of hydroxyurea. Seminars in Oncology 1992, 19:1-10.
41. Maurer-Schultze B., Siebert M., Bassukas I.D. An in vivo study on the synchronizing effect of hydroxyurea. Experimental Cell Research 1988, 174:230-243.
42. Yanamoto S., Iwamoto T., Kawasaki G., Yoshitomi I., Baba N., Mizuno A. Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Letters 2005, 223:67-76.
43. Zhang Y.W., Jones T.L., Martin S.E., Caplen N.J., Pommier Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. Journal of Biological Chemistry 2009, 284:18085-18095.
44. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
45. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nature Reviews Cancer 2003, 3:155-168.
46. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
47. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Development 2001, 15:2177-2196.
48. Donzelli M., Draetta G.F. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Reports 2003, 4:671-677.
49. Nishijima H., Nishitani H., Seki T., Nishimoto T. A dual-specificity phosphatase Cdc25B is an unstable protein and triggers p34(cdc2)/cyclin B activation in hamster BHK21 cells arrested with hydroxyurea. Journal of Cell Biology 1997, 138:1105-1116.
50. Hoffmann I., Clarke P.R., Marcote M.J., Karsenti E., Draetta G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO Journal 1993, 12:53-63.
51. Varmeh-Ziaie S., Manfredi J.J. The dual specificity phosphatase Cdc25B, but not the closely related Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity. Journal of Biological Chemistry 2007, 282:24633-24641.
52. Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M., Draetta G.F. Dual mode of degradation of Cdc25 A phosphatase. EMBO Journal 2002, 21:4875-4884.
53. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
54. Portugal J., Mansilla S., Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Current Pharmaceutical Design 2010, 16:69-78.
55. Gandhi V., Huang P., Chapman A.J., Chen F., Plunkett W. Incorporation of fludarabine and 1-beta-d-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clinical Cancer Research 1997, 3:1347-1355.
56. Wills P.W., Hickey R., Malkas L. Ara-C differentially affects multiprotein forms of human cell DNA polymerase. Cancer Chemotherapy and Pharmacology 2000, 46:193-203.
57. Seymour J.F., Huang P., Plunkett W., Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clinical Cancer Research 1996, 2:653-658.